Viking Therapeutics, Inc VKTX
$29.14
+1.67%
at last close
Market Cap$3.65 billion
P/E Ratio—
Div Yield—
Volume873.9K
52-Week Range
$23.82$43.15
Analyst Ratings
- Consensus
- Buy — 8 Buy · 0 Hold · 0 Sell (8 analysts)
- Avg. Price Target
- $97.25 (+233.7% upside)
Key Stats
- Today's Range
- $28.44 – $29.24
- 50-Day Range
- $23.82 – $43.10
- 52-Week Range
- $23.82 – $43.15
- Volume
- 874K shs
- Average Volume
- 4.80 million shs
- Market Cap
- $3.65 billion
- P/E Ratio
- —
- Dividend Yield
- —
Short Interest
- Short Interest
- 1.04%
- Days to Cover
- 2.69
About Viking Therapeutics, Inc
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, and VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype-selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.
Related Stocks
Compare head-to-head: VKTX vs LLY·VKTX vs JNJ·VKTX vs ABBV·VKTX vs ABT
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.